title: PCSK9 inhibitors in sepsis: a new potential indication?
authors.affiliation: a Student Research Committee, Nanotechnology Research Center, Department of Medical Biotechnology, School of Medicine , Mashhad University of Medical Sciences , Mashhad , Iran.
authors.forename: Amir Abbas
authors.initials: AA
authors.lastname: Momtazi
authors.affiliation: b Department of Hypertension , WAM University Hospital in Lodz, Medical University of Lodz , Lodz , Poland.
authors.forename: Maciej
authors.initials: M
authors.lastname: Banach
authors.affiliation: c Biotechnology Research Center , Mashhad University of Medical Sciences , Mashhad , Iran.
authors.forename: Amirhossein
authors.initials: A
authors.lastname: Sahebkar
mesh_terms: D000818:Animals; D015195:Drug Design; D006801:Humans; D000091362:PCSK9 Inhibitors; D000071449:Proprotein Convertase 9 / Q000378:metabolism; D011973:Receptors, LDL / Q000378:metabolism; D018805:Sepsis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000091362:PCSK9 Inhibitors; D011973:Receptors, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9
keywords: Alirocumab; Evolocumab; LDL receptor; Lipopolysaccharide; PCSK9; Sepsis